恩华药业财务指标

A. 恩华药业的财务分析

规模增长指标
恩华药业过去三年平均销售增长率为14.31%,在所有上市公司排名（984/1710），在其所在的药品零售行业排名为11/16，外延式增长合理
EPS成长性
恩华药业过去EPS增长率为9.35%，在所有上市公司排名（836/1710），在其所在的药品零售行业排名为14/16，公司成长性较差
盈利能力指标
恩华药业过去三年平均盈利能力增长率为36.86%，在所有上市公司排名（630/1710），在所在的药品零售行业排名为 （10/16）。盈利能力合理
EPS稳定性
恩华药业过去EPS稳定性在所有上市公司排名（1/1710），在其所在的药品零售行业排名为1/16 。公司经营稳定较好

B. 帮忙翻译下面中文摘要，万分感谢~~~~~~~~~~~~~

The United States of AmericaDun & Bradstreet Corporationin early twenty-first Centuryhad onChineseenterprise creditanddebt recoverywere investigated,results showed that 67%enterprises are notindependent of thecredit managementdepartment.Furthermore,according to the Ministry of commercedata display,Chineseenterprisesevery year because oflack of creditlead to directand indirecteconomic losses of up to600000000000 yuan.With the development of market economy,enterprise creditsystem in order tograallybecome an importantpart of the social credit system,its importance is increasinglyobvious.China'spharmaceuticalenterprises in seventy or eightypercentare usingcreditmeanscredit,bad debts,accounts receivable recoveryperiodof enterprise development,high cost ofcreditmanagementproblem has beenplaced in front ofeachmedicine enterprise.In the face ofthis phenomenon,the establishment of acomplete and effectivecreditmanagement system is essential.
This paper uses the method ofcombining theory and case studies,through the research and analysisof credit managementtheory,combined with theEn-hua medicinein the pharmaceutical instry,themarket environmentand ,En-hua medicineto design a set ofenterprise development in line with therequirements of themanagement system.The articleis composed of five parts:
The first chapter is the introction,mainlythe research background significance,theframeworkand the domestic and foreignliterature reviewprocess.Inthe literature review at home and abroad,not onlyintroced the domestic and foreigntheory isfamous,and fortheuse ofseveral of the mostwidelycredit managementmodelfor comparative analysis.
The second chapterreviewsthe credit management systemof enterprises,a detailed analysis of therelated conceptsof credit management,and explains that theDSOevaluation indexof the implementation ofenterprise creditmanagementand creditpolicy.
The third chapterour country enterprise management statusof credit,through in-depth analysis ofthe current creditmanagement of the enterprises of our country,find out thedifficulties in implementationof enterprise credit managementand the existing problems.
The fourth chapter is the analysis ofEnhua system diagnosis,discussingEnhua pharmaceuticalBeijingand operatingcharacteristic,carries on the analysis to theinternalmanagement system,En-hua medicineis now the village,find out the advantages and disadvantages,and then introce thedesign ideaof the newsystem.
Design of the fifth chapterEnhua pharmaceuticalnewcredit management systemand perfect,to do a detailed description ofthecredit management departmentand the establishment ofcreditmanagement of all aspects oftheoperation,and to .
The purpose of this paper isan applicablemanagement systemdesign oftherapid developmentasEnhua ,combined with thefinancial managementwith our currentcreditsituation,hope to havesome referencefor such enterprises.

C. 目前深圳股市最具投资潜力的股票有哪些

其实股票原本就不需要那么多地方的户头,做得好,有个深圳的就够了,做不好,即便A,H,S,B都有也照样亏损.人的精力有限,研究5只股票明白了,也可以滚雪球一样越做越大,不要贪多是对的,推荐股票如下:

A 登海种业002041：农业龙头概念，投资组合中必不可少的保值、增值股，拉动内需目前尚未在农村发展起来，原因就是我国农业欠发达状态仍未改变，未来的几十年里，农业都有稳步前进的动力。登海种业、北大荒、新农开发是我国的良种作物、大规模耕地、棉花的三大龙头，考虑到未来发展前景，登海种业比起后者更占优势。并且位于东部沿海地区（山东）对于业绩开展、产品销售都有不可比拟的优势。该股一直维持强势走势，表达了市场对其良好预期
B 张裕A 002869：消费板块里，酒水是上市股票中的大类。白酒市场茅台一家独大，未来价值必然看好。但是这一点大家都抱有信心，因此二级市场上该股不会有什么大幅起落，一定是抗跌、难炒，所以反而不会有太好机会。这个时候选取张裕A其实是出奇制胜的做法。我国葡萄酒市场刚刚开展，并且随着人口素质提高，葡萄酒的健康概念必将深入人心，从而改变国内酒水消费市场的格局，而张裕是我国葡萄酒的绝对第一品牌，其领域优势犹胜茅台。今年张裕收回了解百衲的高级葡萄酒专利品牌，未来的业绩暴增可期
C 万科A 000002 作为国内地产龙头，目前的价格和市盈率显得极为低估，地产毕竟是我国的朝阳行业，经历了高速发展以后略有停滞甚至倒退都是正常的，目前市场对于地产的预期和评价都很不好，所以股价会难得的便宜。今后地产的发展是没有任何人能够否定的 .一句话，长线的话持有地产一定赚钱，并且一定赚大钱